ZVRA (Zevra Therapeutics) Common Stock : $0.01 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Zevra Therapeutics Common Stock?

Zevra Therapeutics's quarterly common stock increased from Jun. 2024 ($0.00 Mil) to Sep. 2024 ($0.01 Mil) but then stayed the same from Sep. 2024 ($0.01 Mil) to Dec. 2024 ($0.01 Mil).

Zevra Therapeutics's annual common stock increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil) and increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.01 Mil).

Zevra Therapeutics Common Stock Historical Data

The historical data trend for Zevra Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zevra Therapeutics Common Stock Chart

Zevra Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Common Stock

Get a 7-Day Free Trial

0.01

Zevra Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Common Stock	Get a 7-Day Free Trial															-	-	-	0.01	0.01

Zevra Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Zevra Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zevra Therapeutics Inc (NAS:ZVRA) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

1GDA:Germany

Address

1180 Celebration Boulevard, Suite 103, Celebration, FL, USA, 34747

Website

https://www.zevra.com

Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.

Executives

Neil F. Mcfarlane	director, officer: President and CEO	C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
R. Laduane Clifton	officer: VP Fin & Corp Controller	C/O KEMPHARM, INC., 1170 CELEBRATION BLVD., #103, CELEBRATION FL 34747
Joshua Schafer	officer: CCO & EVP, Bus. Development	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Timothy J. Sangiovanni	officer: VP, Corporate Controller	C/O KEMPHARM, INC., 2500 CROSSPARK RD, STE E-126, CORALVILLE IA 52241
Watton Corey Michael	director	22045 KAREN STREET, ELKHORN NE 68022
Thomas Anderson	director	215 FIRST STREET, CAMBRIDGE MA 02142
John B Bode	director	C/O TRIBUNE PUBLISHING COMPANY, 202 W. FIRST STREET, LOS ANGELES CA 90012
Douglas W Calder	director	324 S. HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
Wendy L Dixon	director
Tamara A Seymour	director	C/O SIGNAL GENETICS, INC., 5740 FLEET STREET, CARLSBAD CA 92008
Matthew R Plooster	director	2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241
David S Tierney	director	C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080
Richard W Pascoe	director	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Christopher Posner	director	C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Travis C Mickle	director, 10 percent owner, officer: President & CEO	2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241